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1. Introduction 
 
Platelet-derived growth factor (PDGF) is a major mitogen for fibroblasts, 
smooth muscle cells and other cell types (CH Heldin, B Westermark. Physiol 
Rev 79 (1999) 1283). Thus, signaling initiated by its cognate receptor has been 
widely used as a very powerful model system for the study of the signal 
transduction mechanisms controlling cell cycle progression induced by tyrosine 
kinase receptors (RTKs) (CH Heldin, B Westermark. Physiol Rev 79 (1999) 
1283.)and for the understanding of the molecular basis of cellular proliferation. 
Not surprisingly, since when twenty years ago PDGF was identified as the 
cellular homologue of the transforming retroviral v-sis oncogene (SG Devare, et 
al.; Proc Natl Acad Sci USA 80 (1983) 731), genetic alterations have been 
characterized which cause constitutive activation of PDGF receptors, autocrine 
growth stimulation and consequently, human cancer (K Pietras, et al.;. Cancer 
Cell 3 (2003) 439). Consequently, the signaling pathways stimulated by this 
growth factor have been always considered interesting targets for cancer 
treatment. 
In eukaryotic cells, histone proteins organize DNA into nucleosomes, which are 
regular repeating structures of chromatin (PA Marks, et al.; Nature Reviews 
Cancer 1 (2001) 194)  (FIG 1-2). In general, DNA-histone interactions 
condense chromatin and repress transcription, while reduction of these 
interactions relaxes chromatin and enhances gene transcription, by increasing 
the access to the DNA of proteins such as RNA polymerase and transcription 
factors (DH Kim, et al.; J Biochem Mol Biol 36 (2003) 110). Specifically, 
histone acetylation neutralizes the positive charge of conserved lysine residues 
within the NH2-terminal domains of the core histones, therefore diminishing 
interactions between the negatively charged DNA and the histones (I Nusinzon, 
CM Horvath. Sci STKE 2005 296 (2005) re11). Two classes of enzymes, 
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histone acetyltransferases (HATs) (TAB.1) and histone deacetylases (HDACs) 
(TAB.2), reversibly regulate the extent of such modifications (PA Marks, et al.; 
Nature Reviews Cancer 1 (2001) 194) (FIG.3).  
Different studies have recently demonstrated that histones are not the only 
proteins under the control of HATs and HDACs (PA Marks, et al.; Nature 
Reviews Cancer 1 (2001) 194). Thus, substrates for acetylation now include 
several transcription factors, cytosolic proteins such as Tubulin, and proteins 
that shuttle from the nucleus to the cytoplasm such as Importin (F McLaughlin, 
NB La Thangue. Biochem Pharmacol 68 (2004) 1139) (TAB. 3) The control by 
acetylation of the activity and stability of these substrates and, in particular, of 
transcription factors, therefore suggests that HATs and HDACs are able to 
control gene expression also by mechanisms that are distinct from their direct 
effect on chromatin.  
HDAC inhibitors were initially discovered for their ability to reverse the 
malignant phenotype of transformed cells in culture (DH Kim, et al.; J Biochem 
Mol Biol 36 (2003) 110). Since then, huge efforts has been made to unravel the 
identity of the genes controlled by such compounds. Several structural classes 
of HDAC inhibitors have been identified, including short-chain fatty acids such 
as valproic acid  (VPA), cyclic tetrapeptides such as trapoxin A and benzamides 
hydroxamic acids such as trichostatin A (TSA) and suberoylanilide hydroxamic 
acid  (SAHA) (PA Marks, et al.; Nature Reviews Cancer 1 (2001) 194) (TAB. 
4). As expected from their ability to stimulate gene expression by acting on 
histones, HDAC inhibitors induce the levels of tumor suppressor genes (i.e. 
p53, p21 and gelsoline) that cause cell-cycle arrest in G1 and/or G2, apoptosis 
and/or differentiation (I Nusinzon, CM Horvath. Sci STKE 2005 296 (2005) 
re11). Still, more recently it has become clear that they are also able to inhibit 
the expression of tumor activators such as VEGF (DH Kim, et al.; J Biochem 
Mol Biol 36 (2003) 110), c-Myc, Bcl-XL and HIF-1 (MJ Peart, et al.; Proc Natl 
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Acad Sci USA 102 (2005) 3697), suggesting for these drugs a mechanism of 
action more complex then the mere effect on histone acetylation.  
 
2. Materials and methods 
 
2.1. Reagents 
 
Human recombinant PDGF (Intergen) was used at a final concentration of 12.5 
ng ml–1. The HDAC inhibitors SAHA and TSA (Biomol) were added to the 
cells 30 min before stimulation at the indicated concentrations. The Stat 
responsive element (x4) luciferase vector (pStat-Luc) was kindly provided by 
J.E. Jr. Darnell (JF Bromberg, et al.; Mol Cell Biol 18 (1998) 2553). PCR 
amplification of the wild-type Stat3 was cloned in the pCEFL-AU1 expression 
vector. Specific maps and restriction sites  will be made available upon request. 
NIH 3T3 fibroblasts were maintained at 37°C in 5% CO2 in Dulbecco's 
modified Eagle's medium (Invitrogen) supplemented with 10% (v/v) bovine calf 
serum (BioWhittaker), 2 mM L-glutamine, and penicillin-streptomycin 
(Invitrogen). 
 
2.2. Northern blot analysis 
 
After 24 hrs of starvation, NIH3T3 cells were stimulated with 12.5 ng ml-1 
PDGF for various times in absence or after pre-treatment with increasing 
concentration of TSA. Samples were 
then processed as previously described (M Chiariello, et al.; Nat Cell Biol 3 
(2001) 580). As c-myc probe, we used a 450-bp PstI DNA fragment from the 
human c-myc gene (pcDNAIII/GS-Myc-V5, purchased from Invitrogen). 
As VEGF probe, we used a 500-bp Bam HI fragment from the human VEGF 
cDNA (pCEFLP-VEGF). As bcl-XL probe, we used a 500-bp Eco RI fragment 
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from the bcl-XL cDNA (pcDNA4/TO-Bcl-XL, kindly provided by I. Iaccarino). 
The RNA membranes were pre-hybridized for 2 hrs in hybridization solution 
(ExpressHyb, Clontech) at 70 °C. The 32Plabeled  probe for the human c-myc 
gene was added to the blots and hybridized for another 16 hrs at 60 °C. The 
32P-labeled probes of the human VEGF and bcl-XL genes were added to the 
blots and hybridized for another 16 hrs at 68 °C. The blots were washed in 
accordance with manufacturer's specifications of hybridization solution 
(ExpressHyb, Clontech). Accuracy of RNA loading and transfer was confirmed 
by fluorescence under ultraviolet light after staining with ethidium bromide. 
 
2.3. 5-Bromo-2’deoxy-uridine (BrdU) assay 
 
NIH3T3 cells were starved for 24 hrs, stimulated with 12.5 ng ml-1 PDGF for 
15 hrs in absence or after pre-treatment for 30 min with increasing 
concentration of TSA, before incubation with BrdU (10 mmol) for 4 hrs. The 
BrdU assays were performed using the 5- Bromo-2’Deoxy-uridine Labeling and 
Detection Kit I (ROCHE), in accordance with the manufacturer's instructions. 
The slides were mounted in Gel-mount (Biomeda Corp.) and examined with a 
Zeiss Axiophot photomicroscope equipped with epifluorescence. 
 
2.4. Electrophoretic Mobility Shift Assays (EMSA) 
 
Nuclear extracts were obtained from NIH3T3 cells, starved overnight and then 
stimulated with PDGF for various times in absence or after pre-treatment with 
increasing concentration of TSA. Samples were then processed as previously 
described (C Iavarone, et al.; J Biol Chem 278 (2003) 50024). Complementary 
synthetic oligonucleotides containing the STAT3 consensus sequence from 
Santa Cruz Biotechnology were labeled with [γ-32P]-ATP, using T4 
polynucleotide kinase (USB). Labeled oligonucleotides were purified using G25 
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columns (Amersham Biosciences) and used as probes. Complexes were 
analyzed on non-denaturing (5%) polyacrylamide gels in TBE buffer (40 mM 
Tris, 270 mM glycine, 2 mM EDTA, pH 8.0) and run at 13 V/cm at 4 °C. For 
supershift assays, 1 µg of the indicated antiserum was added to the binding 
reaction. 
 
2.5. Western blot analysis and antibodies 
 
Lysates of total cellular proteins were analyzed by protein immunoblotting after 
SDS-PAGE with specific rabbit antisera or mouse monoclonal antibodies. 
Immunocomplexes were detected by the ECL Plus Reagent (Amersham 
Biosciences), by using goat antiserum against rabbit or mouse IgG coupled to 
horseradish peroxidase (Amersham Biosciences). EMSA and Western blot 
analysis were performed using rabbit polyclonal antibodies against STAT3- 
[pSer727] (BIOSOURCE), STAT3-[pTyr705] (Cell Signaling Technology), H3 
(Novous Biologicals), STAT3 and Acetyl-Histone H3 (UPSTATE), STAT3 
C20-X (Santa Cruz Biotechnology). 
 
2.6. Reporter gene assays 
 
For each well, cells were transfected with different expression plasmids together 
with 200 ng of the indicated reporter plasmid and 10 ng of pRL-null as an 
internal control. In all of the cases, the total amount of plasmid DNA was 
adjusted with empty vector. After 16–20 hrs from transfection, firefly and 
Renilla luciferase activities present in cellular lysates from serum-starved cells 
were assayed using the Dual-luciferase reporter system (Promega) and light 
emission was quantified using the 20/20n luminometer (Turner BioSystems). 
 
2.7. Immunofluorescences 
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NIH3T3 cells were starved for 24 hrs, stimulated with 12.5 ng ml-1 PDGF for 1 
hr in absence or after pre-treatment for 30 min with increasing concentration of 
TSA. The cells were fixed for 10 min in 2% paraformaldeide-1% sucrose 
solution at room temperature. Incubation with anti-STAT3 antibodies (Upstate 
Biotecnology) was preformed in accordance with the manufacturer's 
instructions. Slides were washed with PBS and incubated with a secondary anti-
rabbit antibody conjugated to FITC (Jackson ImmunoResearch Laboratories, 
Inc.) for 1 hr at room temperature. The slides were mounted in Gel-mount 
(Biomeda Corp.) and examined with a Zeiss Axiophot photomicroscope 
equipped with epifluorescence. 
 
3. Results 
 
3.1. HDAC inhibitors impede the PDGF-dependent expression of 
different growth promoting genes 
 
A huge amount of data clearly demonstrate that HDACs are able to modulate, 
both up- and down-regulating, the expression of a vast number of genes (MJ 
Peartet al.;. Proc Natl Acad Sci USA 102 (2005) 3697; W Wharton, et al.;  J 
Biol Chem 275 (2000) 33981;  XD Zhang, et al.;  Mol Cancer Ther 3 (2004) 
425). Indeed, differently from what expected from their role on chromatin 
condensation, suppression of HDAC activity by different classes of specific 
inhibitors has clearly demonstrated that these enzymes can also function as 
activators of gene transcription (I Nusinzon, CM Horvath. Proc Natl Acad Sci 
USA 100 (2003) 14742). As an approach to examine, in NIH3T3 cells, the role 
of acetylation in PDGF-dependent transcriptional activity, we took advantage of 
the availability of pharmacological inhibitors of HDACs (PA Marks, et al.;  
Nature Reviews Cancer 1 (2001) 194). In particular, trichostatin A (TSA) 
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potently and specifically inhibits HDACs causing an accumulation of acetylated 
histone species in a variety of mammalian cell lines (M Yoshida, et al.;  J Biol 
Chem 265 (1990) 17174).  
We first sought to confirm the ability of this compound to affect histone 
acetylation in our cellular system, NIH3T3 murine fibroblasts. As shown in 
figure 5A, TSA strongly induced, in a dose-dependent manner, histone H3 
acetylation, after 18 hrs treatment. 
To examine the role of HDACs in PDGF-dependent transcription, we therefore 
assessed the ability of PDGF to modulate the expression of a group of genes 
correlated to cell growth, angiogenesis and cell survival, namely c-myc, VEGF 
and bcl-XL. Cells were starved for 24 hrs and then stimulated with PDGF for up 
to 7 hrs. Northern blot analysis of the extracted total RNA showed an increase 
in the levels of the three genes, although at different time-points after PDGF 
stimulation. Indeed, while as expected (M Chiariello, et al.;. Nat Cell Biol 3 
(2001) 580) PDGF caused a peak of c-myc mRNA after one hour of treatment 
(Fig. 5B), such increase was delayed for VEGF (3 hrs) (Fig. 5C) and bcl-XL (7 
hrs) (Fig. 5D). Still, in all cases such increase was strongly inhibited by 30 min 
pretreatment with increasing concentrations of TSA, establishing a role for 
acetylation in the early and late gene expression processes controlled by PDGF 
(Fig. 5E, 5F and 5G). Also, to confirm that inhibition of gene expression was 
the result of the activity of TSA on HDACs, a second HDAC inhibitor, SAHA, 
was used in a similar experiment, to assess its ability to interfere with PDGF-
dependent stimulation of c-myc expression. As shown in figure 5H, SAHA was 
also very efficient in blocking PDGF-induced c-myc expression, therefore 
strongly supporting that the effects observed for TSA on gene expression are 
dependent on its histone deacetylase activity. Altogether, these results therefore 
show that deacetylase activity is important for both the early and late PDGF-
dependent transcriptional program.  
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3.2. TSA interferes with STAT-dependent transcriptional activity 
induced by PDGF 
 
Signal transducers and activators of transcription (STATs) constitute an 
evolutionarily conserved family of transcription factors latently residing in the 
cytoplasm until specific cell-surface receptors activate them (DE Levy, JE 
Darnell. Nat Rev Mol Cell Biol 3 (2002) 651). Although originally identified as 
mediators of cytokine signaling, STAT proteins are also activated by 
polypeptide growth factors such as PDGF and epidermal growth factor (EGF) 
(Z Zhong, et al.; Science 264 (1994) 95; YZ Wang, et al.;  Oncogene 19 (2000) 
2075). STAT proteins are involved in the regulated expression of numerous 
genes underlying diverse cellular processes ranging from the immune response 
to antiviral protection, apoptosis, proliferation, differentiation and cell survival 
(DE Levy, JE Darnell. Nat Rev Mol Cell Biol 3 (2002) 651).  Among the 
regulated genes, expression of growth-controlling genes such as cyclin D1, bcl-
XL, VEGF and c-myc has been correlated to STAT activity (T Fukada, et al.; 
Embo J 17 (1998) 6670;  M Socolovsky, et al.; Cell 98 (1999) 181). Aberrant 
STAT signaling may also participate in development and progression of human 
cancers (DE Levy, CK Lee. J Clin Invest 109 (2002) 1143) (TAB.5). Indeed, 
several studies have shown that abrogation of STAT3 activity or expression by 
use of dominant negative inhibitors or antisense oligonucleotides leads to 
reversal of the malignant phenotype and apoptosis (DE Levy, CK Lee. J Clin 
Invest 109 (2002) 1143). 
In search for a mechanism that could explain the ability of TSA to inhibit 
PDGF-dependent gene expression, we noticed that all investigated genes are 
under the control of STAT transcription factors (M Funamoto, et al.; J Biol 
Chem 275 (2000) 10561; R Catlett-Falcone, et al.; Immunity  10 (1999) 105; N 
Kiuchi, et al.;  J Exp Med 189 (1999) 63). As numerous recent reports point to a 
positive role for HDACs in cytokine- and STAT-dependent gene regulation(I 
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Nusinzon, CM Horvath. Sci STKE 2005 296 (2005) re11), we decided to 
investigate the possibility that inhibition of HDACs by TSA blocked gene 
expression by directly inhibiting STAT activity. To test this hypothesis, we took 
advantage of the availability of a STAT-dependent luciferase reporter construct, 
pStat-Luc (JF Bromberg, et al.; Mol Cell Biol 18 (1998) 2553). NIH3T3 cells 
were therefore transiently transfected with this reporter, left untreated or treated 
with increasing concentrations of TSA and PDGF (6 hrs), alone or in 
combination (Fig. 6A). While PDGF strongly induced STAT activity in these 
cells, TSA almost abolished such response (Fig. 6A), therefore suggesting that 
HDAC activity is required for optimal PDGF-dependent STAT activation.  
To establish a requirement for HDAC activity for the transcriptional function of 
a specific STAT family member, we also performed a similar experiment in 
presence of transiently transfected STAT3. Due to the very high levels of this 
protein, the observed STAT transcriptional activity in the transfected cells could 
be referred to the overexpressed protein with little or no influence of different 
endogenous STAT family members. We therefore cotransfected NIH3T3 cells 
with pStat-Luc and an expression vector for STAT3, and then left untreated or 
treated with increasing concentrations of TSA and PDGF (6 hrs), alone or in 
combination (Fig. 6B). Again, while PDGF strongly induced STAT3 activity in 
these cells, TSA almost abolished such response (Fig. 6B), therefore suggesting 
that HDAC activity is required for optimal PDGF-dependent activation of 
STAT3. 
 
3.3. Inhibition of HDAC activity does not directly affect STAT3 
phosphorylation, nuclear translocation and DNA-binding 
 
Activation of STAT proteins requires phosphorylation of cytosolic STAT 
monomers on a single tyrosine residue at their C-terminus (DE Levy, JE 
Darnell. Nat Rev Mol Cell Biol 3 (2002) 651) (FIG.7). Once phosphorylated, 
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STAT proteins dissociate from the receptors and form homo- or heterodimers 
that translocate to the nucleus where they interact with other transcriptional 
modulators bound to specific promoter sequences (DE Levy, JE Darnell. Nat 
Rev Mol Cell Biol 3 (2002) 651) (FIG.8). Some STATs also require 
phosphorylation on a conserved serine residue for maximal transcriptional 
activation (WJ Leonard, JJ O'Shea. Annual Review of Immunology 16 (1998) 
293).  
To determine whether HDAC inhibition alters PDGF-stimulated tyrosine or 
serine phosphorylation of STAT3, we performed both western blot analysis 
with phospho-specific antibodies directed against tyrosine705 or serine727 of this 
protein. Cells were incubated with PDGF for up to 45 min, with or without 
pretreatment for 30 min with increasing concentrations of TSA. As shown in 
figure 9, PDGF-dependent phosphorylation of STAT3 was not affected by 
TSA, when normalized to endogenous STAT3 protein levels.  
To determine weather treatment with TSA affects STAT3 sub-cellular 
localization, NIH3T3 cells were treated with PDGF alone or in association with 
TSA and then examined by immunofluorescence analysis using a specific anti-
STAT3 antibody. In our system, TSA treatment of PDGF-stimulated cells had 
no effect on sub-cellular localization of STAT3 (Fig. 10). In this regard, it is 
important to notice that, although even PDGF could not induce nuclear 
translocation of STAT3 it has been clearly demonstrated that, in specific 
cellular systems, STAT proteins are equally distributed between the cytoplasm 
and the nucleus and such balance is not affected by stimuli that are able to 
activate them (T Meyer, et al.; Exp Cell Res 272 (2002) 45).  
Next, we sought to investigate, by electrophoretic mobility shift assay (EMSA), 
the possibility that inhibition of HDAC activity could directly affect STAT3 
DNA-binding ability. As expected, PDGF stimulation rapidly induced the 
binding of STAT homo- and hetero-dimers to a double-strand oligonucleotide 
containing a typical STAT responsive element (Fig. 11A), reaching a peak at 15 
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min. Specifically, three major STAT-containing DNA binding complexes were 
observed, represented by STAT3 homo-dimers (slowest migrating complexes), 
STAT1 homo-dimers (farthest migrating complexes) and STAT1/STAT3 
hetero-dimers (complexes with the intermediate mobility)  (HB Sadowski, et al.; 
Science 261 (1993) 1739) (Fig. 5A). To further verify the presence of STAT3 in 
such complexes, we also performed supershift analysis by incubating the 
binding reactions with antibodies specific to the STAT3 protein (Fig. 5B). As 
an additional control, we also verified that the binding of the complexes to the 
DNA was specific, as it was efficiently competed by addition of an excess of 
unlabeled oligonucleotide (Fig. 5C). As shown in figure 5D, pretreatment of 
NIH3T3 cells with progressively increasing concentrations of TSA ultimately 
indicated that the activity of HDACs had no effect on PDGF-stimulated STAT3 
(and STAT1) DNA binding activity. Our data therefore indicate that inhibition 
of HDAC activity does not directly affect the mechanisms by which PDGF 
activates STAT3 or stimulates its DNA-binding ability. 
 
3.4. Inhibition of HDAC activity prevents PDGF-dependent cellular 
proliferation 
 
HDAC inhibitors have repeatedly demonstrated their efficacy to arrest cellular 
growth of multiple cell lines (PA Marks, et al.; Nature Reviews Cancer 1 (2001) 
194; DH Kim, et al.; J Biochem Mol Biol 36 (2003) 110). Based on the 
evidence that these drugs profoundly affected PDGF-dependent expression of 
different genes related to proliferation and survival (see above), we sought to 
examine the role of acetylation on PDGF-induced NIH3T3 cell proliferation. To 
this aim, we analyzed bromodeoxyuridine (BrdU) incorporation in quiescent 
NIH3T3 cells stimulated with PDGF in absence or after pre-treatment with 
increasing concentration of TSA. Cells were first starved for 24 hrs to arrest 
them in the G0/G1-phase of the cell cycle, left untreated or pre-treated with 
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increasing concentrations of TSA and then stimulated with PDGF for 15 hrs, a 
timeframe in which NIH3T3 cells enter S-phase and duplicate their DNA (M 
Chiariello, et al.; Biochem J 349 (2000) 869). As shown in Fig. 6, the addition 
of TSA was able to completely inhibit S-phase progression of stimulated 
NIH3T3 cells, even at the lowest concentration used (50 µM). TSA was 
therefore a strong inhibitor of the early phases of cell cycle progression of 
NIH3T3 cells stimulated with PDGF. 
 
4. Discussion 
 
Although many different genetic defects exist in human tumors, they frequently 
seem to converge on a more limited number of signal transduction pathways 
often controlling the expression of a certain number of cancer promoting genes. 
The possibility to modulate the expression of such genes has therefore become a 
rationale target for the treatment of cancer. In recent years, a number of 
structurally divergent classes of HDAC inhibitors have been identified that 
induce cell cycle arrest, terminal differentiation and/or apoptosis in various 
cancer cell lines and inhibit tumor growth in animal models (F McLaughlin, NB 
La Thangue. Biochem Pharmacol 68 (2004) 1139). Though, in this respect, it is 
important to note that several non-histonic proteins, among which different 
transcription factors, are direct substrates of acetylation and, in turn, of HDACs  
(F McLaughlin, NB La Thangue. Biochem Pharmacol 68 (2004) 1139). 
By using TSA, one of the first HDAC inhibitors identified, we show that 
deacetylase activity is necessary for the expression of genes correlated to the 
growth stimulatory (c-myc), anti-apoptotic (bcl-XL) and pro-angiogenetic 
(VEGF) activity of PDGF. Reasonable candidates for mediating the inhibition 
of the expression of such genes are STAT family members. Indeed, all the 
investigated genes are under the control of these transcription factors (M 
Funamoto, et al.; J Biol Chem 275 (2000) 10561;  R Catlett-Falcone, et al.;. 
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Immunità 10 (1999) 105;  N Kiuchi, et al.;  J Exp Med 189 (1999) 63), 
suggesting that HDAC inhibitors may negatively influence the activity of STAT 
proteins. Although many papers have recently addressed the role of HDACs in 
the regulation of STAT activation, the issue is far from being solved. Indeed, 
many contrasting data are present in literature relative to the effect of HDAC 
inhibitors on STAT family members: while in some systems HDAC inhibitors 
interfere with STAT tyrosine and serine phosphorylation and nuclear 
translocation (L Klampfer, et al.;  Mol Cancer Res 1 (2003) 855; L Klampfer, et 
al.; J Biol Chem 279 (2004) 36680), other papers indicate that these drugs have 
no direct effect on nuclear translocation, DNA-binding activity and tyrosine and 
serine phosphorylation of STAT proteins (I Nusinzon, CM Horvath. Proc Natl 
Acad Sci USA 100 (2003) 14742; S Sakamoto, et al.;. J Biol Chem 279 (2004) 
40362; HM Chang, ET AL.; Proc Natl Acad Sci USA 101 (2004) 9578). 
Complicating even more this story, recent data report that, upon cytokine 
stimulation, STAT3 undergo acetylation of a single amino acid residue 
providing an alternative mechanism for its activation (ZL Yuan, et al.; Science 
307 (2005) 269; R Wang, et al.;  J Biol Chem 280 (2005) 11528), altogether 
pointing to a positive role for HDACs in STAT-dependent gene transcription. In 
our experimental conditions, HDAC activity seems to positively affect STAT 
activation as TSA strongly inhibits PDGF-dependent activation of STAT 
transcriptional potential, in particular of STAT3, in NIH3T3 cells. These data 
therefore support a role for STAT proteins in mediating HDACs effects on 
PDGF transcriptional program. Nonetheless, inhibition of STAT activity by 
TSA was not correlated to a deficit in STAT3 tyrosine and serine 
phosphorylation, nucleo-cytoplasmic shuttling and DNA-binding activity. TSA 
also inhibits selected interferon β-stimulated immediate early genes that are 
activated by STAT1 and STAT2 although, in line with our results, the drug does 
not affect tyrosine phosphorylation of the transcription factors or their binding 
to the endogenous ISG54 promoter  (S Sakamoto, et al.; J Biol Chem 279 
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(2004) 40362). Conversely, TSA prevents the binding of RNA polymerase II to 
this promoter (S Sakamoto, et al.; J Biol Chem 279 (2004) 40362). Further work 
will be required to ascertain a role for STAT proteins in HDACs-dependent 
recruitment of RNA polymerase II to the promoter of specific genes. 
Numerous data indicate that the exposure of quiescent cells to PDGF causes the 
rapid activation of a number of signaling pathways controlling re-initiation of 
DNA synthesis and cell proliferation (M Chiariello, et al.; Nat Cell Biol 3 
(2001) 580; M Chiariello, et al.; Biochem J 349 (2000) 869). We show that one 
such pathway requires HDAC activity as TSA completely prevents PDGF-
dependent cellular proliferation. Intriguingly, Bowman and collaborators 
recently showed that STAT3-mediated c-Myc expression is required for PDGF-
induced mitogenesis (T Bowman et al.; Proc Natl Acad Sci USA 98 (2001) 
7319).Together, these observations provide support for a requirement for 
histone deacetylase activity in the control of a STAT-dependent transcriptional 
program induced by PDGF, culminating in the increased expression of growth-
related genes and, consequently, cellular proliferation.  
In contrast to the idea of HDACs as regulators of global chromatin organization, 
the effects of HDAC inhibitors on gene expression are surprisingly highly 
selective, leading to modification of the transcription rate of only a limited 
number of expressed genes (F McLaughlin, NB La Thangue. Biochem 
Pharmacol 68 (2004) 1139). As a consequence, there is ongoing evaluation of 
several HDAC inhibitor compounds in phase I and II clinical trials in a vast 
array of human tumors (www.clinicaltrials.gov) (F McLaughlin, NB La 
Thangue. Biochem Pharmacol 68 (2004) 1139). Among these drugs, SAHA has 
already shown significant anticancer activity at doses well tolerated by patients 
(WK Kelly, et al.; Clin Cancer Res 9 (2003) 3578).  
In the case of PDGF, both solid and hematological malignancies have been 
identified that present constitutive activation of the signaling pathways 
controlled by its cognate receptor (K Pietras, et al.; Cancer Cell 3 (2003) 439). 
 20 
The involvement of HDACs in the PDGF-dependent mitogenic transcriptional 
program and cell proliferation may therefore represent a valid rationale for the 
use of these drugs in cancers in which deregulated PDGF receptor signaling 
represents the cause of the tumor or strongly sustain their maintenance through 
anti-apoptotic and pro-angiogenic processes. 
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FIG. 1. The Atomic Structure of the Nucleosome Core Particle 
Each strand of DNA is shown in different shade of blue. The DNA makes 1.7 turns around the 
histone octamer to form an overall particle with a disk-like structure. 
Sepideh Khorasanizadeh. Cell  2004, 116 :259–272  
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FIG. 2 | The wide range of histone modifications. (A) Chromatin is formed by nucleosome subunits 
comprising an octameric core of histones around which ~1.8 superhelical turns of DNA are wrapped.DNA 
binds to the positively charged histone surfaces through H-bonds and electrostatic interactions. In the 11-nm 
chromatin fibre, successive nucleosomes are separated by 10–80 base pairs of linker DNA.Histone H1, 
which binds to nucleosomes and adjacent linker DNA, can mediate further condensation into the 30-nm 
chromatin fibre. 
 (B) The amino-termini of histones H3 and H4 protrude from the nucleosome core ad contain dense clusters 
of modifiable residues.Residues are coloured on welldocumented modification sites,with red indicating 
where acetylation or phosphorylation increase acidity and blue indicating methylation.Note that H3 Lys 9 
(pink) can be either acetylated or methylated.Pale green shading highlights putative ‘modification cassettes’ 
and boxes indicate potential ‘methyl–phos binary switches’. Further possible modifications are listed 
elsewhere (Felsenfeld & Groudine, 2003; Fischle et al, 2003a).  
(C) Histone modifications create new chemical environments. For example, lysine acetylation (red) 
neutralizes the positive charge of the Næ group and introduces the carbonyl oxygen,which is a potential H-
bond acceptor.Lysine methylation (blue) increases both 
hydrophobicity and the cationic nature of the Næ group.Depending on the modifying enzyme, lysines can 
be mono-, di- or tri-methylated.  
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FIG. 3. Role of HAT and HDAC in transcriptional regulation. Histone 
modification by HAT and HDAC. 
  
 
FIG. 4.  Transcriptional repression and activation in chromatin. Yellow circles represent core 
histone octamers ; in the upper panel, acetylated histone tails (dark red) are depicted emerging from the 
octamer. DNA is purple, and the solid black arrow represents complex movement. Both histone 
acetyltransferase (HAT ; activation) and HDAC (repression) require several cofactors (for DNA binding, 
for recruitment of the complex, for remodelling of the DNA helix to reduce the accessibility of 
transcription factors) for their activity  
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Table 1 a Histones that are the primary in vitro substrates for a given HAT are bold; other histones listed 
are acetylated weakly or in a secondary manner. 
b Asterisks indicate proteins for which HAT activity has been suggested indirectly or demonstrated in an 
incomplete manner. Elp3 can acetylate all four histones but has only been tested with them individually in 
in-gel assays. The HAT function of HBO1 has primarily been shown by the in vitro free histone H3/H4-
acetylating activity of a purified human complex containing it, although recombinant GST-HBO1 (and the 
complex) did weakly acetylate nucleosomes. Finally, TFIIIC220 was identified as a HAT only in in-gel 
assays, and its activity has not been confirmed by recombinant protein studies as of this writing. ND, not 
determined.c S. John and J. L. Workman, unpublished result. 
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Table 3. Acetylated protein substrates of 
HDACs 
Table 2. Characteristics of histone deacetylases 
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Table 4 Shown are the features of four groups of HDACi, including in vitro efficiency of the 
members, and general structure. Oxamflatin, apicidine and depsipeptide (FK228) are cyclic 
hydroxamic acid-containing tetrapeptides, i.e. hybrids between hydroxamic acids and cyclic 
tetrapeptides. They are grouped in accordance with their major feature. The cyclic 
tetrapeptides/epoxides form a heterogeneous group of compounds with a high degree of 
overlap, indicating that many of the members have both features. 
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FIG. 5. HDAC inhibitors prevent PDGF-dependent expression of different growth-promoting genes. (A) TSA 
induces histone H3 acetylation. NIH3T3 cells were starved for 24 hrs and pretreated or not with increasing 
concentrations of TSA for 15 hrs. Nuclear extracts were then assayed by Western blot, using the specific anti-acetyl-
Histone H3 (upper panel) and anti-H3 (bottom panel) antibodies. (B) Analysis of c-myc mRNA expression in NIH3T3 
cells stimulated for the indicated durations with PDGF. (C) Analysis of VEGF mRNA expression in NIH3T3 cells 
stimulated for the indicated durations with PDGF. (D) Analysis of bcl-XL mRNA expression in NIH3T3 cells 
stimulated for the indicated durations with PDGF. (E) Analysis of c-myc mRNA in NIH3T3 cells pretreated with 
increasing concentrations of the specific HDAC inhibitor, TSA, and then stimulated for 1 hr with PDGF. (F) Analysis 
of VEGF mRNA in NIH3T3 cells pretreated with increasing concentrations of TSA and then stimulated for 3 hrs with 
PDGF. (G) Analysis of bcl-XL mRNA in NIH3T3 cells pretreated with increasing concentrations of TSA and then 
stimulated for 7 hrs with PDGF. (H) Analysis of c-myc mRNA in NIH3T3 cells pretreated with increasing 
concentrations of the specific HDAC inhibitor, SAHA, and then stimulated for 1 hr with PDGF. -, no treatment.  
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FIG. 6. TSA inhibits STAT transcriptional activity induced by PDGF. (A) NIH3T3 cells were transfected with a 
STAT-responsive luciferase construct, pStat-Luc (200 ng). The day after transfection, cells were left untreated or 
treated with combinations of increasing concentrations of TSA and PDGF (6 hrs), as indicated. (B) Same as in (A), but 
cotransfecting cells with pStat-Luc and an expression vector for STAT3.  
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FIG. 7 | STAT domain structure and protein binding sites.   a | The core structure (amino acids 130–712) shows 
binding of a STAT1 dimer to DNA and the location of binding sites of various proteins in various domains. The 
amino-terminal structure, the placement of which in the intact structure is undefined, also interacts with various 
partners, as does the carboxy-terminal transactivation domain, the structure of which is unknown. Modified with 
permission from Ref. 36 © 1998 American Association for the Advancement of Science, and from Ref. 161 © 1998 
Elsevier Science Ltd. CBP, CREB binding protein; IRF, interferon regulatory factor; Mcm, minichromosome 
maintenance; Nmi, N-Myc interactor; PIAS, protein inhibitor of activated STAT. b | STAT structure. STAT, signal 
transducer and activator of transcription. SH2, Src-homology-2 domain.  
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FIG. 8. | Variations in mechanisms of STAT activation   
Tyrosine phosphorylation of signal transducers and activators of transcription (STAT) proteins at or around residue 
700 occurs in response to cytokine receptors through Janus kinases (JAKs). However, at least several dozen receptors 
with intrinsic tyrosine kinase activity (RTKs), such as those for epidermal growth factor (EGF) and platelet-derived 
growth factor (PDGF), seem to be able to mediate the activation of STAT proteins. Apparently, this activation can be 
direct (as in the case of STAT1 activation by PDGF receptor) or indirect. The latter case involves the recruitment of 
complexes of proteins to the phosphorylated RTK. Non-receptor tyrosine kinases (NRTKs), such as Src — the first 
tyrosine kinase to be discovered — are among the recruited proteins. STAT3 and Src can interact independently and 
STAT3 probably becomes phosphorylated by Src on the EGF and PDGF receptors. Furthermore, it is clear that seven-
transmembrane (7TM) receptors can, after binding their peptide or short polypeptide ligands, also activate STAT 
proteins152-154. It has been proposed again that the tyrosine kinase involved is Src — or perhaps the JAKs become 
activated by associating with 7TM receptors155-157. STAT1, STAT3, STAT4, STAT5 and STAT6 homodimerize. 
STAT1 and STAT2, and STAT1 and STAT3 can form heterodimers, and several STAT proteins can form tetramers 
(or potentially higher order complexes). 
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FIG. 9. TSA does not interfere with STAT3 tyrosine705 and serine727 phosphorylation upon PDGF stimulation. 
NIH3T3 cells were starved for 24 hrs, then left untreated or treated with combinations of increasing concentrations of 
TSA and PDGF, as indicated. Total lysates were assayed by Western blot using specific antibodies: anti-STAT3-
[pSer727] (upper panel), anti-STAT3-[pTyr705] (middle panel) and anti-STAT3 (bottom panel). -, no treatment; α-, 
antibody against. 
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FIG. 10. TSA does not alter the sub-cellular localization of STAT3. NIH3T3 cells were seeded on coverslips and, 
after 24 hrs, transferred to serum-free medium for an additional 18 hrs. Cells were pretreated with increasing 
concentrations of TSA and then stimulated with PDGF for 1 hr. Subsequently, cells were fixed and analyzed by 
immunofluorescence for endogenous STAT3 (a-STAT3) and nuclear staining with DAPI. Comb., combination; a-, 
antibody against. 
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FIG. 11. PDGF-stimulated STAT3 DNA binding activity is independent of HDAC activity. NIH3T3 cells were 
serum-starved for 24 hrs and then treated as indicated. Nuclear extracts were subjected to elecrophoretic mobility shift 
assay (EMSA) with a 32P-labeled probe containing a STAT3-responsive element. (A) Nuclear extracts from NIH3T3 
cells stimulated with PDGF for the indicated durations. (B) Supershift analysis with a monoclonal anti-STAT3 
antibody of NIH3T3 nuclear extracts, upon PDGF stimulation for the indicated duration. (C) Control of specificity for 
the EMSA analysis, using the unlabeled oligonucleotides as competitors in concentration five to fifty fold-molar 
excess versus the probe. NIH3T3 cells were stimulated for 15 min with PDGF. (D) EMSA of NIH3T3 nuclear extract 
upon pretreatment with increasing concentrations of the TSA and stimulation with PDGF for 15 min. The position of 
the complexes containing STAT3/STAT3 (3:3) and STAT1/STAT1 (1:1) homo-dimers, and STAT1/STAT3 (1:3) 
hetero-dimers are indicated. -, no treatment; α-, antibody against; Comp., competitor.  
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FIG. 12. PDGF-stimulated STAT3 DNA binding activity is independent of HDAC activity. NIH3T3 cells were 
serum-starved for 24 hrs and then treated as indicated. Nuclear extracts were subjected to elecrophoretic mobility shift 
assay (EMSA) with a 32P-labeled probe containing a STAT3-responsive element. (A) Nuclear extracts from NIH3T3 
cells stimulated with PDGF for the indicated durations. (B) Supershift analysis with a monoclonal anti-STAT3 
antibody of NIH3T3 nuclear extracts, upon PDGF stimulation for the indicated duration. (C) Control of specificity for 
the EMSA analysis, using the unlabeled oligonucleotides as competitors in concentration five to fifty fold-molar 
excess versus the probe. NIH3T3 cells were stimulated for 15 min with PDGF. (D) EMSA of NIH3T3 nuclear extract 
upon pretreatment with increasing concentrations of the TSA and stimulation with PDGF for 15 min. The position of 
the complexes containing STAT3/STAT3 (3:3) and STAT1/STAT1 (1:1) homo-dimers, and STAT1/STAT3 (1:3) 
hetero-dimers are indicated. -, no treatment; α-, antibody against; Comp., competitor.  
